Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.54 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.54 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.54 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | DGKA | P23743 | 1/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.49 |
| ▸ | TERT | O14746 | 2/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL465985 | 1.00 | PRKCA (0.54) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL465982 | 0.91 | LMNA (0.62) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL15228719 | 0.91 | LMNA (0.62) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL14263115 | 0.91 | LMNA (0.62) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL8394182 | 0.91 | LMNA (0.62) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL8396305 | 0.91 | LMNA (0.62) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL8394932 | 0.91 | LMNA (0.62) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL872500 | 0.91 | LMNA (0.62) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL8394166 | 0.89 | LMNA (0.59) | PRKCAPRKCEPRKCQPRKCDLMNA | |
| SCHEMBL4458170 | 0.87 | PRKCA (0.56) | PRKCAPRKCEPRKCQPRKCDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10632086-B2 | Methods and compositions for treating Raynaud's disease | NEXMED HOLDINGS, INC. (US) | 2020-04-28 | — | — | US | claimed |
| US-20180333377-A1 | METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE | NEXMED HOLDINGS, INC. (US) | 2018-11-22 | — | — | US | claimed |
| EP-2693877-A1 | METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE | NexMed Holdings, Inc. (US) | 2014-02-12 | — | — | EP | claimed |
| WO-2012139033-A1 | METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE | NEXMED HOLDINGS, INC. (US) | 2012-10-11 | — | — | WO | claimed |
| US-10632086-B2 | Methods and compositions for treating Raynaud's disease | NEXMED HOLDINGS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180333377-A1 | METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE | NEXMED HOLDINGS, INC. (US) | 2018-11-22 | — | — | US | disclosed |
| US-9855231-B2 | Methods and compositions for treating Raynaud's disease | NEXMED HOLDINGS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9517218-B2 | Methods and compositions for treating raynaud's disease | NEXMED HOLDINGS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160331761-A1 | METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE | NEXMED HOLDINGS, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160081954-A1 | METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE | NEXMED HOLDINGS, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160067266-A1 | STABILIZED COMPOSITION FOR TREATING PSORIASIS | NEXMED HOLDINGS, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| US-9220701-B2 | Stabilized composition for treating psoriasis | NEXMED HOLDINGS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| EP-2106805-A1 | Antifungal nail coat and method of use | Nexmed Holdings, Inc. (US) | 2009-10-07 | — | — | EP | disclosed |
| US-7560489-B2 | Stabilized prostaglandin E composition | NEXMED HOLDINGS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20090099266-A1 | Antifungal nail coat and method of use | NEXMED HOLDINGS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-7462362-B2 | Antifungal nail coat and method of use | NEXMED HOLDINGS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20080090911-A1 | Stabilized prostaglandin E composition | NEXMED HOLDINGS, INC. | 2008-04-17 | — | — | US | disclosed |
| US-20070264319-A1 | Transdermal Antiemesis Delivery System, Method and Composition Therefor | NEXMED HOLDINGS, INC. | 2007-11-15 | — | — | US | disclosed |
| US-20060067898-A1 | Antifungal nail coat and method of use | NEXMED HOLDINGS, INC. | 2006-03-30 | — | — | US | disclosed |
| US-20050181030-A1 | Topical stabilized prostaglandin E compound dosage forms | NEXMED HOLDINGS, INC. | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060067898-A1 | Antifungal nail coat and method of use | PIK3C3, POLR1C, NACA | PRKCA 3641/4885PRKCE 2881/4885PRKCQ 3936/4885 |
| US-20160331761-A1 | METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE | PTGER1, PTGES, PTGS1 | PRKCA 2078/4885PRKCE 1775/4885PRKCQ 1649/4885 |
| US-20180333377-A1 | METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE | PTGER1, PTGES, PTGS1 | PRKCA 2078/4885PRKCE 1775/4885PRKCQ 1649/4885 |
| US-20090099266-A1 | Antifungal nail coat and method of use | NACA, DPM1, PIK3C3 | PRKCA 4552/4885PRKCE 4417/4885PRKCQ 4549/4885 |
| US-20160081954-A1 | METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE | PTGER1, PTGES, PTGS1 | PRKCA 2078/4885PRKCE 1775/4885PRKCQ 1649/4885 |
| US-10632086-B2 | Methods and compositions for treating Raynaud's disease | PTGER1, PTGES, PTGS1 | PRKCA 2078/4885PRKCE 1775/4885PRKCQ 1649/4885 |
| US-20050181030-A1 | Topical stabilized prostaglandin E compound dosage forms | PTGES, PTGIS, PTGER1 | PRKCA 3587/4885PRKCE 3065/4885PRKCQ 2401/4885 |
| US-20080090911-A1 | Stabilized prostaglandin E composition | PTGES, PTGER2, PTGER1 | PRKCA 1170/4885PRKCE 645/4885PRKCQ 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.